muramylnac-ala-isogln-lys-tripeptide has been researched along with lipoteichoic acid in 1 studies
| Studies (muramylnac-ala-isogln-lys-tripeptide) | Trials (muramylnac-ala-isogln-lys-tripeptide) | Recent Studies (post-2010) (muramylnac-ala-isogln-lys-tripeptide) | Studies (lipoteichoic acid) | Trials (lipoteichoic acid) | Recent Studies (post-2010) (lipoteichoic acid) |
|---|---|---|---|---|---|
| 50 | 4 | 1 | 1,625 | 12 | 646 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boneca, IG; de Jong, DJ; Dharancy, S; Ferwerda, G; Girardin, SE; Jéhanno, M; Mengin-Lecreulx, D; Netea, MG; Philpott, DJ; Sansonetti, PJ; Van Der Meer, JW; Werts, C | 1 |
1 other study(ies) available for muramylnac-ala-isogln-lys-tripeptide and lipoteichoic acid
| Article | Year |
|---|---|
The frameshift mutation in Nod2 results in unresponsiveness not only to Nod2- but also Nod1-activating peptidoglycan agonists.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adaptor Proteins, Signal Transducing; Amino Acid Motifs; Animals; Cell Line; Crohn Disease; Down-Regulation; Frameshift Mutation; Genotype; Homozygote; Humans; Hydrolysis; Interleukin-10; Intracellular Signaling Peptides and Proteins; Leukocytes, Mononuclear; Lipopolysaccharides; Macrophages; Mice; Mice, Inbred C57BL; Models, Biological; Models, Chemical; Mutation; NF-kappa B; Nod1 Signaling Adaptor Protein; Nod2 Signaling Adaptor Protein; Peptides; Peptidoglycan; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Teichoic Acids; Toll-Like Receptors; Transfection | 2005 |